Clinical trial
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
NCT00040599 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00040599 |
|---|---|
| Title | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer |
| Official title | A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumor |
| Intervention type | Drug |
| Interventions | hMN14 (labetuzumab) |
| Enrollment | 72 |
| Start date | Jan 1, 2000 |
| Completion | Jan 1, 2004 |
| First posted | Jul 3, 2002 |
| Last update posted | Aug 19, 2021 |
| Countries | Germany, Hungary, Sweden, Switzerland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: